Relay Therapeutics, Inc. (RLAY)

Over the past six months, Relay Therapeutics' stock price increased significantly by 116.52%. Positive clinical data for zovegalisib in breast cancer and vascular anomalies, along with a Q4 2025 earnings beat, drove analyst upgrades and price target raises. The initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 was a significant milestone. A new $96.2 million shelf registration introduced caution regarding potential dilution. As of April 7, 2026, the share price was $13.48, a substantial increase from $2.00 on April 8, 2025.

Relay Therapeutics, as a clinical-stage company, does not experience traditional product demand seasonality. Revenue is tied to clinical pipeline progress, collaborations, and potential commercialization, rather than seasonal purchasing patterns.

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming drug discovery. They operate in the Healthcare sector, specifically Biotechnology and Pharmaceuticals & Biotech, using their Dynamo platform to develop small molecule therapies. Their pipeline includes RLY-2608 (Zovegalisib) for breast cancer and vascular malformations, Lirafugratinib (RLY-4008) for FGFR2-altered cancers (outlicensed to Elevar Therapeutics), RLY-8161 for NRAS-driven solid tumors, and an αGal chaperone program for Fabry diseases.

Relay Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.

Relay Therapeutics has maintained a positive brand reputation, with a "Moderate Buy" consensus rating from analysts. Positive sentiment is driven by clinical trial data for zovegalisib in breast cancer and vascular anomalies. There have been no reported events that negatively impacted their brand reputation in the past year.

Relay Therapeutics, Inc. has a diverse ownership structure, predominantly held by institutional investors, with approximately 78.46% to 96.98% of the stock held by institutions. Insiders hold around 2.33% to 26.65% of the stock, with retail investors holding a smaller percentage. Major institutional owners include SB Investment Advisers (uk) Ltd, Commodore Capital Lp, Point72 Asset Management, L.P., BlackRock, Inc., Casdin Capital, LLC, and Vanguard Group Inc. Significant individual/insider owners include Svf Pauling Cayman Ltd and Third Rock Ventures III LP.